Regulated necrosis: disease relevance and therapeutic opportunities

M Conrad, JPF Angeli, P Vandenabeele… - Nature reviews Drug …, 2016 - nature.com
The discovery of regulated cell death presents tantalizing possibilities for gaining control
over the life–death decisions made by cells in disease. Although apoptosis has been the …

Role of poly (ADP‐ribose) polymerase 1 (PARP‐1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors

P Pacher, C Szabó - Cardiovascular drug reviews, 2007 - Wiley Online Library
Accumulating evidence suggests that the reactive oxygen and nitrogen species are
generated in cardiomyocytes and endothelial cells during myocardial ischemia/reperfusion …

Nitrosative stress and pharmacological modulation of heart failure

P Pacher, R Schulz, L Liaudet, C Szabó - Trends in pharmacological …, 2005 - cell.com
Dysregulation of nitric oxide (NO) and increased oxidative and nitrosative stress are
implicated in the pathogenesis of heart failure. Peroxynitrite is a reactive oxidant that is …

Role of oxidative DNA damage and repair in atrial fibrillation and ischemic heart disease

L Hu, Z Wang, C Carmone, J Keijer… - International journal of …, 2021 - mdpi.com
Atrial fibrillation (AF) and ischemic heart disease (IHD) represent the two most common
clinical cardiac diseases, characterized by angina, arrhythmia, myocardial damage, and …

Chemical regulation of epigenetic modifications: opportunities for new cancer therapy

YG Zheng, J Wu, Z Chen… - Medicinal research …, 2008 - Wiley Online Library
Epigenetics is concerned about heritable changes in gene expression without alteration of
the coding sequence. Epigenetic modification of chromatin includes methylation of genomic …

Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury

S Korkmaz, T Radovits, E Barnucz, K Hirschberg… - Circulation, 2009 - Am Heart Assoc
Background—The role of the nitric oxide/cGMP/cGMP–dependent protein kinase G pathway
in myocardial protection and preconditioning has been the object of intensive investigations …

PARP inhibitors: new tools to protect from inflammation

V Giansanti, F Donà, M Tillhon, AI Scovassi - Biochemical pharmacology, 2010 - Elsevier
Poly (ADP-ribosylation) consists in the conversion of β-NAD+ into ADP-ribose, which is then
bound to acceptor proteins and further used to form polymers of variable length and …

Poly (ADP-ribose) polymerase inhibition in acute lung injury. A reemerging concept

C Szabo, V Martins, L Liaudet - American journal of respiratory cell …, 2020 - atsjournals.org
PARP1, the major isoform of a family of ADP-ribosylating enzymes, has been implicated in
the regulation of various biological processes including DNA repair, gene transcription, and …

Poly (ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications

CA de La Lastra, I Villegas… - Current …, 2007 - ingentaconnect.com
Poly (ADP-ribose) polymerase (PARP) comprise of a family of enzymes which catalyses poly
(ADPribosyl) ation of DNA-binding proteins. To date, seven isoforms have been identified …

Beneficial effects of a novel ultrapotent poly (ADP-ribose) polymerase inhibitor in murine models of heart failure

P Pacher, L Liaudet, JG Mabley… - International …, 2006 - spandidos-publications.com
Overactivation of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) contributes to
the development of cell dysfunction and tissue injury in various pathophysiological …